

# SkinBioTherapeutics PLC

07:28 31 Jul 2020

## SkinBioTherapeutics reports progress in cosmetic programme and food supplement trial

SkinBioTherapeutics PLC (LON:SBTX) has updated investors on the progress of its cosmetic skincare programme and a psoriasis food supplement trial.

The AIM-listed firm said Sederma, its partner in the cosmetics programme and a division of Croda International PLC (LON:CRDA), has successfully replicated the lysate manufacturing process and achieved the same performance from the company's SkinBiotix technology and is now working to validate a scale up of the manufacturing process at different volume levels.

**WATCH:** SkinBioTherapeutics assessing options for a 'rapid trial' of its food supplement

SkinBio said the project is progressing in line with the original plan and has not been impacted by the coronavirus pandemic, adding that any results from the programme will be sold to Croda's global portfolio of Personal Care customers, with the company receiving tiered royalties based on global sales revenues on any products developed in the partnership.

Meanwhile, the firm said in light of current restrictions on non-coronavirus related human studies, it has established a protocol for its 'self-managed' psoriasis food supplement trial and was proceeding with the study.

Participants suffering from mild to moderate psoriasis will be invited to participate in a human study in which they will be provided with samples of AxisBiotix Ps to self-administer over eight weeks and track the impact of the food supplement on their skin condition. They will then submit their findings periodically through a bespoke mobile app, avoiding the need for clinical attendance.

SkinBio said this will accelerate the timing of readout compared to the previously envisaged conventional study, and if the findings were positive this will allow for a "significantly earlier commercial launch than originally planned". The trial is expected to begin in early 2021.

"We have seen significant positive progress made on the first of our commercial programmes in recent weeks. In such an important scientific milestone, it is reassuring and provides validation of our approach that Sederma has been able to replicate the activity of the SkinBiotix technology and is pushing ahead with the next steps of the project", SkinBio chief executive Stuart Ashman said in a statement.

"In addition, establishing a clear pathway to commencing a food supplement trial to manage symptoms associated with psoriasis is a great step forward for our collaboration with Winclove. The progress made in such a short period of time is testament to the combined efforts of the SkinBioTherapeutics and Winclove team", he added.

**Price:** 24.8

**Market Cap:** £31.76 m

### 1 Year Share Price Graph



August 2019 February 2020 August 2020

### Share Information

**Code:** SBTX

**Listing:** AIM

<b>52 week</b>	<b>High</b>	<b>Low</b>
	26.35	5

**Sector:** Pharma & Biotech

**Website:** [www.skinbiotherapeutics.com](http://www.skinbiotherapeutics.com)

### Company Synopsis:

*SkinBioTherapeutics is a life science company focused on skin health. The Company's proprietary platform technology, SkinBiotix®, is based upon discoveries made by CEO Dr. Catherine O'Neill and Professor Andrew McBain at The University of Manchester. The SkinBioTherapeutics' platform applies research discoveries made on the activities of lysates derived from probiotic bacteria when applied to skin.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of SkinBioTherapeutics PLC named herein, including the promotion by the Company of SkinBioTherapeutics PLC in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to

Twenty	Five	Thousand	dollars	(\$25,000).
--------	------	----------	---------	-------------